You are here: Industry Insights > Fosmanogepix

News List

Pfizer Acquires Amplyx Pharmaceuticals contractpharma
April 30, 2021
Pfizer has acquired Amplyx Pharmaceuticals, a privately-held company dedicated to the development of therapies for immune system disorders.
Amplyx Announces Positive Top-line Data in Antifungal Fosmanogepix Trial americanpharmaceuticalreview
July 27, 2020
Amplyx Pharmaceuticals announced positive topline data following the completion of its Phase 2 clinical trial of fosmanogepix as a first-line treatment for patients with invasive fungal infections caused by Candida.
Fast Track designation granted to fosmanogepix for seven indications europeanpharmaceuticalreview
September 12, 2019
Both the intravenous and oral formulations of the antifungal candidate, fosmanogepix, have been granted Fast Track designation by the FDA.
FDA Grants Fast Track to Amplyx for IV and Oral Formulations of Fosmanogepix americanpharmaceuticalreview
September 10, 2019
Amplyx Pharmaceuticals announced the U.S. Food & Drug Administration (FDA) has granted Fast Track designations for both the intravenous (IV) and oral formulations of the company's lead antifungal candidate...